Stock Scorecard



Stock Summary for Biogen Inc (BIIB) - $182.93 as of 3/23/2026 7:00:52 PM EST

Total Score

10 out of 30

Safety Score

63 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BIIB

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BIIB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BIIB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BIIB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BIIB (63 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 7
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BIIB

Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports By Reuters 3/23/2026 5:13:00 PM
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies 3/23/2026 1:40:00 PM
Biogen Inc. Stock Stifel CNS Forum: $190 Target Price Driven by Tau Pipeline Pivot 3/23/2026 1:12:00 PM
Biocatalysis Market Accelerates with Rising Demand in Pharmaceuticals, Food Processing, and Biofuels | Top Companies are Biocatalysts Limited, Novozymes A/S, Codexis, Inc 3/23/2026 12:39:00 PM
BridgeBio heart drug lands late-breaking ACC slot with survival data 3/23/2026 11:09:00 AM
Biogen (BIIB) Valuation Check As New Lecanemab Persistence Data Support Alzheimer’s Franchise Potential 3/23/2026 6:12:00 AM
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026 3/23/2026 2:07:00 AM
RTW Investments Increases Cogent Biosciences Stake to 2.7% of Portfolio - News and Statistics 3/22/2026 5:08:00 PM
Swiss Life Asset Management Ltd Sells 21,970 Shares of Biogen Inc. $BIIB 3/22/2026 11:23:00 AM
Biogen Leqembi at-home maintenance dose for Alzheimer's available 3/22/2026 3:37:00 AM

Financial Details for BIIB

Company Overview

Ticker BIIB
Company Name Biogen Inc
Country USA
Description Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 12/31/2025
Next Earnings Date 5/7/2026

Stock Price History

Last Day Price 182.93
Price 4 Years Ago 276.92
Last Day Price Updated 3/23/2026 7:00:52 PM EST
Last Day Volume 2,214,268
Average Daily Volume 1,061,256
52-Week High 202.41
52-Week Low 110.04
Last Price to 52 Week Low 66.24%

Valuation Measures

Trailing PE 20.67
Industry PE 27.97
Sector PE 98.23
5-Year Average PE 13.09
Free Cash Flow Ratio 8.92
Industry Free Cash Flow Ratio 41.11
Sector Free Cash Flow Ratio 25.46
Current Ratio Most Recent Quarter 2.68
Total Cash Per Share 20.50
Book Value Per Share Most Recent Quarter 124.36
Price to Book Ratio 1.46
Industry Price to Book Ratio 11.21
Sector Price to Book Ratio 36.25
Price to Sales Ratio Twelve Trailing Months 2.69
Industry Price to Sales Ratio Twelve Trailing Months 3.86
Sector Price to Sales Ratio Twelve Trailing Months 8.03
Analyst Buy Ratings 14
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 146,759,000
Market Capitalization 26,846,623,870
Institutional Ownership 98.05%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.71%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 19.20%
Annual Earnings Growth -20.76%
Reported EPS 12 Trailing Months 8.78
Reported EPS Past Year 15.29
Reported EPS Prior Year 16.47
Net Income Twelve Trailing Months 1,293,389,000
Net Income Past Year 1,293,389,000
Net Income Prior Year 1,632,200,000
Quarterly Revenue Growth YOY -7.10%
5-Year Revenue Growth -6.11%
Operating Margin Twelve Trailing Months 19.60%

Balance Sheet

Total Cash Most Recent Quarter 3,008,500,000
Total Cash Past Year 3,008,500,000
Total Cash Prior Year 2,375,000,000
Net Cash Position Most Recent Quarter -3,278,300,000
Net Cash Position Past Year -3,278,300,000
Long Term Debt Past Year 6,286,800,000
Long Term Debt Prior Year 4,547,200,000
Total Debt Most Recent Quarter 6,286,800,000
Equity to Debt Ratio Past Year 0.74
Equity to Debt Ratio Most Recent Quarter 0.74
Total Stockholder Equity Past Year 18,256,800,000
Total Stockholder Equity Prior Year 16,716,000,000
Total Stockholder Equity Most Recent Quarter 18,256,800,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 2,050,800,000
Free Cash Flow Per Share Twelve Trailing Months 13.97
Free Cash Flow Past Year 2,050,800,000
Free Cash Flow Prior Year 2,515,700,000

Options

Put/Call Ratio 3.31
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.54
MACD Signal 0.43
20-Day Bollinger Lower Band 158.70
20-Day Bollinger Middle Band 180.02
20-Day Bollinger Upper Band 201.35
Beta 0.14
RSI 43.82
50-Day SMA 150.87
150-Day SMA 196.70
200-Day SMA 210.88

System

Modified 3/23/2026 6:32:07 PM EST